Moderna FY2024 EPS Reduced by Brookline Capital Management

Moderna, Inc. (NASDAQ:MRNA) – Brookline Capital Management dropped their FY2024 earnings per share estimates for shares of Moderna in a research report issued to clients and investors on Monday, January 13th. Brookline Capital Management analyst L. Cann now forecasts that the company will post earnings per share of ($9.15) for the year, down from their previous estimate of ($9.12). The consensus estimate for Moderna’s current full-year earnings is ($9.30) per share. Brookline Capital Management also issued estimates for Moderna’s Q4 2024 earnings at ($2.85) EPS, FY2025 earnings at ($8.56) EPS, FY2026 earnings at ($2.00) EPS, FY2027 earnings at $1.30 EPS and FY2028 earnings at $5.31 EPS.

Several other research firms also recently weighed in on MRNA. Bank of America reissued an “underperform” rating and issued a $41.00 price objective on shares of Moderna in a report on Tuesday, December 10th. Argus cut shares of Moderna from a “buy” rating to a “hold” rating in a report on Wednesday, December 18th. Wolfe Research began coverage on Moderna in a report on Friday, November 15th. They set an “underperform” rating and a $40.00 price target on the stock. Needham & Company LLC reaffirmed a “hold” rating on shares of Moderna in a research note on Friday, November 8th. Finally, UBS Group lowered their target price on Moderna from $108.00 to $96.00 and set a “buy” rating on the stock in a research note on Wednesday, January 8th. Four equities research analysts have rated the stock with a sell rating, thirteen have given a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Moderna has a consensus rating of “Hold” and a consensus target price of $75.58.

Moderna Stock Down 2.9 %

Shares of NASDAQ MRNA opened at $33.76 on Thursday. The business has a 50-day moving average price of $41.11 and a 200 day moving average price of $67.32. The stock has a market cap of $12.99 billion, a PE ratio of -5.80 and a beta of 1.60. The company has a quick ratio of 4.20, a current ratio of 4.39 and a debt-to-equity ratio of 0.05. Moderna has a 52-week low of $31.94 and a 52-week high of $170.47.

Moderna (NASDAQ:MRNA) last posted its earnings results on Thursday, November 7th. The company reported $0.03 EPS for the quarter, beating analysts’ consensus estimates of ($1.89) by $1.92. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The firm had revenue of $1.90 billion for the quarter, compared to the consensus estimate of $1.25 billion. During the same period last year, the firm posted ($1.39) EPS. The company’s revenue was up 3.8% on a year-over-year basis.

Insider Activity at Moderna

In related news, insider Shannon Thyme Klinger sold 1,418 shares of the stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $42.79, for a total value of $60,676.22. Following the sale, the insider now directly owns 19,717 shares of the company’s stock, valued at approximately $843,690.43. This represents a 6.71 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders sold 2,664 shares of company stock valued at $115,210 in the last ninety days. Corporate insiders own 15.20% of the company’s stock.

Institutional Trading of Moderna

Several institutional investors and hedge funds have recently modified their holdings of the business. State Street Corp increased its stake in shares of Moderna by 12.1% during the 3rd quarter. State Street Corp now owns 16,847,212 shares of the company’s stock worth $1,125,899,000 after purchasing an additional 1,823,276 shares in the last quarter. Wellington Management Group LLP increased its position in Moderna by 21.0% during the third quarter. Wellington Management Group LLP now owns 5,224,685 shares of the company’s stock worth $349,166,000 after buying an additional 906,114 shares in the last quarter. Two Sigma Advisers LP acquired a new position in shares of Moderna in the third quarter worth $23,825,000. International Assets Investment Management LLC lifted its position in shares of Moderna by 10,687.1% in the third quarter. International Assets Investment Management LLC now owns 319,514 shares of the company’s stock valued at $21,353,000 after acquiring an additional 316,552 shares in the last quarter. Finally, Douglas Lane & Associates LLC boosted its stake in shares of Moderna by 62.9% during the fourth quarter. Douglas Lane & Associates LLC now owns 773,804 shares of the company’s stock valued at $32,175,000 after acquiring an additional 298,715 shares during the last quarter. Hedge funds and other institutional investors own 75.33% of the company’s stock.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.